How Teva Pharmaceutical Is Attacking the Generics to Defend Its Turf

NEW YORK (TheStreet) -- Teva Pharmaceutical's ADR (TEVA) continues to benefit from the delay in FDA approval of a generic version of its top-selling multiple sclerosis drug Copaxone. The approval delay has given Teva more time to switch patients to a new, three-times-per-week version of the drug.

A low-cost version of Copaxone will be approved eventually, and bulls and bears argue over how much of an impact this will have on the stock's valuation.

At Tuesday's close at $54.95, shares of Teva are up 37% for the year and just short of the 52-week high of $55.24. Teva reports second-quarter earnings on July 31. Here's what to listen for.

Yellen's Testimony Tanks; Trade, Don't Invest: Best of Kass

10 Best Used Luxury Cars Under $30,000

What Would a Tesla-BMW Deal Look Like?

Here's How You Invest in Your Ice Cream and Eat It, Too

As the FDA mulls over the generic version of Copaxone, Teva is taking steps to develop new drugs in its pipeline. It is also pursuing acquisitions in order to make up for any lost revenue due to generic Copaxone.

Wall Street is expecting Teva to report earnings of $1.19 per share, flat from one year ago, on a 3% year-over-year bump in total revenue to $5.06 billion. So far this year, Teva has maintained its 2014 revenue guidance in the range of $19.3 billion to $20.3 billion, which at the midpoint represents a drop of 2.5% from 2013.

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon